Zealand Pharma A/S (ZEAL) 2015年年度报告「NASDAQ」.pdf

1、Frompeptide topatient ANNUAL REPORT 2015Zealand Pharma A/SZEALAND PHARMA A/S ANNUAL REPORT 2015Management reviewZEALAND PHARMA A/S ANNUAL REPORT 2015Management review1Lyxumia20mcginjectionlixisentatideContents Highlights in 2015 and early 2016 Progress on all frontsFinancial statements Financial sta

2、tements 50Notes 55Statements 78Company information 80Corporate matters Board of Directors and senior management 34Risk management and internal control 38Corporate Governance,Corporate Social Responsibility and Human Resources 41Shareholder information 44Financial review 48Our portfolio Portfolio ove

3、rview 142015 achievements 162016 achievements and news outlook 17Out-licensed portfolio 18Proprietary pipeline 24Our business Value creation at Zealand Turning peptides into medicines 2Key figures,financial highlights and 2016 guidance 4Letters from the Chairman and the CEO 6Zealands strategy 10Key

4、Performance Indicators 11Our business has considerably matured since the beginning of 2015.Under our agreement with Sanofi,both lixisenatide and LixiLan have been filed for US approvals with prospects of significant revenue growth and a path to profitability for our company in the years to come.We h

5、ave advanced our own pipeline,including initiation of two Phase II trials with two Zealand invented investigational medicines.All in line with our strategy for accelerated value creation,where we will take select specialty peptide medicines all the way through registration ourselves for the benefit

6、of patients and shareholders.Expansion of clinical competencies,including in-house regulatory,quality and medical expertise New Board members with broad international competenciesNew CEO and senior management teamDoubling of shareholders to 10,000*US ownership share of 17-20%*92%increase in market v